AstraZeneca Exanta "not approvable"
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
AstraZeneca's anticoagulant Exanta (ximelagatran) is "not approvable," the company announces Oct. 8. The agency's decision, reached two weeks ahead of the Oct. 23 user fee date, is in line with the Cardiovascular & Renal Drugs Advisory Committee's Sept. 10 recommendation against approval for all three indications being sought. Liver safety has been a key safety concern with Exanta; AstraZeneca previously indicated that labeling would likely include requirements for regular liver function monitoring (1Pharmaceutical Approvals Monthly Jan. 1, 2004, p. 17). During an Oct. 6 conference call, VP Hamish Cameron described the situation as "a clash between what might be termed regulatory medicine and clinical medicine"...
You may also be interested in...
Exanta Oral & Sub-Q Cleared In France; U.S. NDA Seeks Oral Formulation Only
Proposed European labeling for AstraZeneca’s anticoagulant Exanta does not call for regular liver monitoring.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Timely Acquisition Keeps Germany's Dermapharm Growing
With its Branded Pharmaceuticals division negatively impacted by the end of the COVID-19 pandemic, the timely acquisition of supplements firm Arkopharma ensured Dermapharm recorded double-digit sales growth in 2023.